<?xml version='1.0' encoding='utf-8'?>
<document id="23226041"><sentence text="Determinants to optimize response to clopidogrel in acute coronary syndrome."><entity charOffset="37-48" id="DDI-PubMed.23226041.s1.e0" text="clopidogrel" /></sentence><sentence text="The inhibition of platelet function by antiplatelet therapy determines the improvement of the survival of patients with clinically evident cardiovascular disease" /><sentence text=" Clopidogrel in combination with aspirin is the recommended standard of care for reducing the occurrence of cardiovascular events in patients with acute coronary syndromes undergoing percutaneous coronary intervention"><entity charOffset="1-12" id="DDI-PubMed.23226041.s3.e0" text="Clopidogrel" /><entity charOffset="33-40" id="DDI-PubMed.23226041.s3.e1" text="aspirin" /><pair ddi="false" e1="DDI-PubMed.23226041.s3.e0" e2="DDI-PubMed.23226041.s3.e0" /><pair ddi="false" e1="DDI-PubMed.23226041.s3.e0" e2="DDI-PubMed.23226041.s3.e1" /></sentence><sentence text=" However, major adverse cardiovascular events including stent thrombosis occur in patients taking clopidogrel and aspirin"><entity charOffset="98-109" id="DDI-PubMed.23226041.s4.e0" text="clopidogrel" /><entity charOffset="114-121" id="DDI-PubMed.23226041.s4.e1" text="aspirin" /><pair ddi="false" e1="DDI-PubMed.23226041.s4.e0" e2="DDI-PubMed.23226041.s4.e0" /><pair ddi="false" e1="DDI-PubMed.23226041.s4.e0" e2="DDI-PubMed.23226041.s4.e1" /></sentence><sentence text=" A growing body of evidence demonstrates that high post-treatment platelet reactivity on antiplatelet treatment is associated with increased risk of adverse clinical events" /><sentence text=" Clopidogrel requires conversion to active metabolite by cytochrome P450 isoenzymes"><entity charOffset="1-12" id="DDI-PubMed.23226041.s6.e0" text="Clopidogrel" /></sentence><sentence text=" The active metabolite inhibits ADP-stimulated platelet activation by irreversibly binding to P2Y(12) receptors" /><sentence text=" Recently, the loss-of-function CYP2C19*2 allele has been associated with decreased metabolization of clopidogrel, poor antiaggregant effect, and increased cardiovascular events"><entity charOffset="102-113" id="DDI-PubMed.23226041.s8.e0" text="clopidogrel" /></sentence><sentence text=" In high risk vascular patients, the CYP2C19*2 polymorphism is a strong predictor of adverse cardiovascular events and particularly of stent thrombosis" /><sentence text=" Prospective studies evaluating if an antiplatelet treatment tailored on individual characteristics of patients, CYP2C19*2 genotypes, platelet phenotype, drug-drug interaction, as well as traditional and procedural risk factors, are now urgently needed for the identification of therapeutic strategies providing the best benefit for the single subject" /><sentence text="" /></document>